ChenGuang Biotech Group 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Qingguo Lu

최고 경영자

CN¥2.1m

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	21.3%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	1.5yrs

최근 관리 업데이트

Recent updates

CEO

Qingguo Lu (65 yo)

no data

테뉴어

CN¥2,118,500

보상

Mr. Qingguo Lu is Chairman & GM of ChenGuang Biotech Group Co., Ltd.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Qingguo Lu	Chairman & GM	no data	CN¥2.12m	21.3% CN¥ 875.7m
Jing Zhou	CFO, Secretary of the Board & Director	5.6yrs	CN¥678.00k	1.71% CN¥ 70.4m
Tao Zhao	Employee Representative Supervisor	no data	데이터 없음	0.011% CN¥ 450.6k
Ying Lu	Non-Independent Director	1.5yrs	CN¥3.97m	데이터 없음
Wei Gao	Supervisory Board Chairman	no data	CN¥652.40k	0.015% CN¥ 631.5k
Shaohua Wang	Non Employee Representative Supervisor	no data	데이터 없음	데이터 없음
Xiaofeng Dai	Independent Director	1.5yrs	CN¥49.00k	데이터 없음
Hong Niu	Independent Director	1.5yrs	CN¥49.00k	데이터 없음
Liangqiu Li	Independent Director	1.5yrs	CN¥49.00k	데이터 없음

1.5yrs

평균 재임 기간

44yo

평균 연령

경험이 풍부한 이사회: 300138 의 이사회는 경험(평균 재직 기간 1.5 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

ChenGuang Biotech Group 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

ChenGuang Biotech Group Co., Ltd., Annual General Meeting, May 09, 2024

Chenguang Biotech Group Co., Ltd. Announces Management Appointment

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Third quarter 2024 earnings released: CN¥0.072 loss per share (vs CN¥0.19 profit in 3Q 2023)

Investor sentiment improves as stock rises 15%

ChenGuang Biotech Group Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 18%

New minor risk - Profit margin trend

ChenGuang Biotech Group Co., Ltd. to Report First Half, 2024 Results on Aug 27, 2024

ChenGuang Biotech Group Co., Ltd. Approves Cash Dividend on A Shares for the Year 2023, Payable on 13 June 2024

ChenGuang Biotech Group Co., Ltd. Approves Cash Dividend for the Year 2023

ChenGuang Biotech Group Co., Ltd., Annual General Meeting, May 09, 2024

Full year 2023 earnings released: EPS: CN¥0.90 (vs CN¥0.81 in FY 2022)

Investor sentiment deteriorates as stock falls 16%

ChenGuang Biotech Group Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Full year 2023 earnings released: EPS: CN¥0.91 (vs CN¥0.81 in FY 2022)

ChenGuang Biotech Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 18, 2024

ChenGuang Biotech Group Co., Ltd. (SZSE:300138) commences an Equity Buyback Plan for CNY 100 million worth of its shares, under the authorization approved on November 17, 2023.

Third quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.18 in 3Q 2022)

ChenGuang Biotech Group Co., Ltd. to Report Q3, 2023 Results on Oct 24, 2023

Second quarter 2023 earnings released: EPS: CN¥0.31 (vs CN¥0.25 in 2Q 2022)

ChenGuang Biotech Group Co., Ltd. to Report First Half, 2023 Results on Aug 18, 2023

Chenguang Biotech Group Co., Ltd. Announces Management Appointment

ChenGuang Biotech Group Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 17 May 2023

First quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.20 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥0.82 (vs CN¥0.67 in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.12 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.23 in 2Q 2021)

Insufficient new directors

Chenguang Biotech Group Co., Ltd. Announces 2021 Final Cash Dividend Proposal on A Shares, Payable on 1 June 2022

Insufficient new directors

First quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.15 in 1Q 2021)

Chenguang Biotech Group Co., Ltd. Approves Cash Dividend

Full year 2021 earnings released: EPS: CN¥0.67 (vs CN¥0.55 in FY 2020)

ChenGuang Biotech Group Co., Ltd. Announces Final Dividend For the Year 2021

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.11 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.19 in 2Q 2020)

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령